Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2017

View Archived Issues

Alligator begins preclinical development of ATOR-1017 for metastasizing cancer

First-in-human results on PET imaging of dopamine transporter with [18F]LBT-999

ETX-0282/cefpodoxime proxetil combination shows promise against resistant Gram-negative uropathogens

Full OlympiAD results show benefit of PARP inhibition with olaparib in breast cancer

Cefepime/S-02030 combination efficacious in murine bacteremia model

Domainex expands MAP4K4 inhibitor partnership with Imperial College London

BioTime's pivotal European trial of Renevia meets primary endpoint

Long-term data from phase I/II data of GS-010 in Leber's hereditary optic neuropathy

Actelion presents preclinical data for novel bacterial topoisomerase inhibitor ACT-051

Aldeyra reports phase IIb results for ADX-102 in allergic conjunctivitis

ACEA completes phase I trial of AC-0058

Takara Bio initiates phase I/II study of TBI-1501 for relapsed or refractory ALL

Janssen begins first-in-human study of JNJ-64007957 for relapsed or refractory multiple myeloma

Leids Universitair Medisch Centrum presents recombinant serine protease variants

Adaptimmune and Immunocore identify TRPM1 derivatives

Lilly initiates phase I study of LY-3325656 for type 2 diabetes

Cancer Research Technology and AstraZeneca divulge GLS inhibitors

SBIR grant supports Hillhurst's development of HBI-002 to prevent delayed graft function

Chiesi Farmaceutici discloses muscarinic M3 receptor antagonists and beta2-adrenoceptor agonists

Tirabrutinib granted FDA orphan drug designation for chronic lymphocytic leukemia

Novartis discloses Janus kinase inhibitors

REGN-1979 receives U.S. orphan drug designation for diffuse large B-cell lymphoma

Amylyx initiates phase II trial of AMX-0035 in ALS

Abivax to receive loan to support development of Ebola hyperimmune candidate

MedImmune initiates phase I trial of MEDI-3506 for COPD

Pfizer gains European commercialization rights to Cresemba from Basilea

TiGenix partners with Crohn's disease and ulcerative colitis patient advocacy groups

LGCL-1, a novel FFA4 receptor agonist for treating metabolic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...